Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Annals of Oncology(2023)10.1016/j.annonc.2023.10.048Source: DataRank Database

LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network is a research paper published in Annals of Oncology (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: bronzeLinked Datasets (2)DataCite Reuse (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Thierry Lecomte ORCID,Julien Hadoux ORCID,Patricia Niccoli,Léa Saban-Roche ORCID,E. Gaye

Live enrichment

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttp://www.annalsofoncology.org/article/S0923753423041923/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0923753423041923?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0923753423041923?httpAccept=text/plain

Additional file 1 of Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis

10.6084/m9.figshare.25210667.v1figshare

Additional file 1 of Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis

10.6084/m9.figshare.25210667figshare